trending Market Intelligence /marketintelligence/en/news-insights/trending/izfb4xwpjmkofq4w19z4iw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Roche hemophilia drug sees positive phase 3 study results

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Roche hemophilia drug sees positive phase 3 study results

Roche Holding Ltd.'s hemophilia A drug candidate met its primary- and- secondary endpoints in a phase 3 study.

ACE910, or emicizumab, showed a significant reduction in the number of bleeds over time in 12-year-old patients and older when compared to no prophylactic treatment.

The company also said it had resolved the thrombosis concerns raised earlier during the trial.